Trifarotene (brand name Aklief 0.005% cream) is a prescription fourth-generation topical retinoid approved by the FDA for acne vulgaris on the face, chest, shoulders, and back in patients 9 and older. By selectively targeting retinoic acid receptor-gamma (RAR-γ), it clears microcomedones and reduces inflammation while minimizing systemic drug exposure over large body areas.

How does Aklief (trifarotene) work for acne?

Aklief (trifarotene 0.005% cream) works by selectively binding to retinoic acid receptor-gamma (RAR-γ), which comprises roughly 90% of all retinoic acid receptors in the epidermis. This targeted binding normalizes follicular keratinization, rapidly dissolves clogged microcomedones, suppresses localized inflammation, and accelerates cellular renewal without unnecessary binding to alpha or beta receptors.

While first-generation retinoids like tretinoin activate all retinoic acid receptor subtypes indiscriminately, fourth-generation trifarotene demonstrates over 20-fold selectivity for RAR-γ compared to RAR-α and RAR-β. In acne pathophysiology, abnormal cell stickiness blocks pores, trapping sebum and encouraging Cutibacterium acnes proliferation. By activating RAR-γ directly inside follicular keratinocytes, trifarotene normalizes skin desquamation, clearing microscopic plugs before they become swollen blemishes.

The clinical potency of this selective mechanism was established in two landmark Phase III randomized, double-blind trials published in the Journal of the American Academy of Dermatology (Tan et al., 2019, PMID 30802558). Evaluating 2,420 patients with moderate acne, once-daily trifarotene 50 mcg/g cream achieved investigator success rates of 29.4% and 42.3% on facial acne (vs. 19.5% and 25.7% for vehicle) and 35.7% and 42.6% on truncal acne (vs. 25.0% and 29.9% for vehicle). Mean inflammatory lesion counts declined by up to 66.2% on the face and 65.4% on the trunk at week 12.

How long does it take for Aklief to work?

Most patients begin seeing noticeable reductions in acne lesions within 2 to 4 weeks of once-daily evening use, with peak clinical clearance developing between 12 and 24 weeks. Mild retinization symptoms like flaking or erythema typically peak within the first two weeks before the skin adapts and cellular turnover stabilizes.

Understanding the expected clinical timeline helps prevent premature discontinuation:

Weeks 1 to 2: Accelerated cell turnover can prompt temporary purging as sub-surface microcomedones surface. Redness and peeling peak during this initiation window.
Weeks 4 to 8: Visible papules flatten, overall oiliness moderates, and skin texture becomes smoother.
Weeks 12 to 24: Peak clearance is reached, with substantial reductions across inflammatory and comedonal lesions.
Weeks 24 to 52: Ongoing maintenance prevents recurrent follicular blockages while promoting dermal remodeling.

Long-term tolerability was verified in the 52-week SATURN study published in the Journal of the American Academy of Dermatology (Blume-Peytavi et al., 2020, PMID 31306527). Across 453 patients, overall success rates reached 65.1% for facial acne and 66.9% for truncal acne by week 52. Crucially, local irritation reactions peaked early (weeks 1 to 2 on the face, weeks 2 to 4 on the trunk) before declining steadily to mild baseline levels.

Can Aklief be used for back and chest acne?

Yes, Aklief is the first topical retinoid specifically formulated and FDA-approved to treat both facial and truncal acne (affecting the chest, shoulders, and back). Its rapid metabolic breakdown in the liver prevents significant systemic drug accumulation, making it safe to apply across expansive body surface areas.

Truncal breakouts represent an underdiagnosed burden in acne care. An epidemiological study published in the Journal of Clinical and Aesthetic Dermatology (Del Rosso et al., 2007, PMID 20725554) revealed that 50% to 60% of patients with facial acne also have truncal acne. However, approximately 1 in 4 patients (25%) do not voluntarily disclose their body breakouts during medical consultations.

Traditional retinoids present challenges on the body because truncal skin is thick, and covering the back and chest requires large product quantities. Trifarotene overcomes this via unique pharmacokinetics: it is rapidly degraded by human liver microsomes, with a half-life of roughly 5 minutes. As a result, systemic drug levels remain below quantifiable limits even when applied across large body surfaces, providing potent local clearing without systemic risk.

Is trifarotene better than tretinoin?

Trifarotene is not necessarily better than tretinoin for isolated facial acne, but it offers distinct clinical advantages for patients with widespread body acne or atrophic scarring. While tretinoin has decades of general anti-aging and acne data, trifarotene provides unmatched epidermal receptor selectivity and documented efficacy across large truncal areas.

Although no head-to-head randomized trials directly compare trifarotene to tretinoin, their pharmacological differences are distinct. Tretinoin activates all three retinoic acid receptor subtypes, whereas trifarotene specifically targets RAR-γ. Furthermore, trifarotene has demonstrated unique clinical benefits for acne scarring. In the 24-week double-blind LEAP study published in Dermatology and Therapy (Dreno et al., 2023, PMID 37838987), once-daily trifarotene achieved a -15.5% reduction in total atrophic acne scar count compared to a +1.4% increase with vehicle (P < 0.001), showing early collagen remodeling alongside lesion clearance.

Retinoid	Generation	Receptor Target	FDA Truncal Approval	Typical Concentrations	Primary Use Cases
Trifarotene (Aklief)	4th Generation	Selective RAR-γ (>20x)	Yes (Face, Chest, Back)	0.005% cream	Facial & truncal acne; atrophic scar remodeling
Tretinoin (Retin-A)	1st Generation	Non-selective (RAR-α, β, γ)	No (Facial only)	0.025%, 0.05%, 0.1%	Facial acne; fine lines, photoaging, pigmentation
Adapalene (Differin)	3rd Generation	Selective RAR-β, RAR-γ	No (Facial only)	0.1% (OTC), 0.3% (Rx)	Mild comedonal acne; higher barrier tolerability
Tazarotene (Tazorac)	3rd Generation	Selective RAR-β, RAR-γ	No (Facial only)	0.05%, 0.1%	Stubborn cystic acne; plaque psoriasis

For an in-depth comparison of third-generation options, read our guide on tazarotene vs. tretinoin. If you are introducing a prescription retinoid for the first time, review our protocol for tretinoin for beginners.

How much does Aklief cost without insurance?

Without insurance, a 45g pump of brand-name Aklief retails for approximately $920, with GoodRx discounts bringing the cash price to around $690. However, commercially insured patients can access the Galderma CAREConnect copay card for as little as $20 per refill, while uninsured patients can pay approximately $90.

Because Aklief is a patented single-source brand without a generic alternative, retail cash costs are high. However, manufacturer savings programs help make it affordable:

Galderma CAREConnect (Insured): Commercially insured patients can pay as little as $20 per prescription fill, or $90 if their plan denies coverage.
Galderma CAREConnect (Cash-Pay): Uninsured patients can use the card at participating pharmacies to purchase a 45g container for approximately $90.
Government Insurance: Patients enrolled in Medicare, Medicaid, or Tricare cannot legally utilize manufacturer copay cards.

For patients seeking digital prescriptions without in-person dermatologist wait times, several teledermatology services offer online evaluations:

Platform	Service Model	Consultation Fee	Medication Fulfillment	Best For
Nurx	Asynchronous photo consult for branded and generic acne treatments	$40 annual medical consult fee; bills commercial insurance	Coordinates brand Aklief through partner mail-order specialty pharmacy or local retail pharmacy; accepts copay card	Insured patients seeking branded medications with copay assistance
Honeydew Care	Comprehensive teledermatology specializing in persistent and truncal acne	$40–$60/month clinical membership; accepts commercial insurance	Board-certified dermatologists route Aklief prescriptions to mail-order pharmacies with manufacturer savings applied	Patients with stubborn truncal breakouts needing continuous doctor access
Ro Derm	Custom prescription skincare and branded teledermatology	Flat-fee digital medical evaluation; cash-pay and pharmacy routing	Evaluates skin photos; coordinates branded prescriptions or custom compounded alternatives	Patients wanting transparent cash pricing and medical follow-ups
Curology	Custom compounding service (tretinoin, azelaic acid, clindamycin, spironolactone)	From $29.95/month ($59.90 billed bi-monthly); 30-day trial ($5.45 shipping)	Direct home shipping of custom compounded formulas; does not dispense branded Aklief	Patients seeking affordable custom blends without retail pharmacy navigation

To learn how asynchronous photo consultations operate, review our guide on how telehealth skincare works. If your breakouts flare cyclically along the lower face, explore our guides on hormonal acne and clascoterone (Winlevi) for acne.

Frequently asked questions

Does Aklief cause skin purging? Yes, Aklief (trifarotene) can cause initial skin purging during the first 2 to 4 weeks of therapy. Because trifarotene accelerates cellular turnover and rapidly desquamates keratinocytes, pre-existing microscopic comedones deep within hair follicles are pushed to the surface simultaneously, causing temporary inflammatory flare-ups before long-term clearing occurs.

Can you use Aklief every day? Yes, Aklief is prescribed for once-daily application in the evening on clean, completely dry skin. However, dermatologists often recommend starting every other evening or three nights per week for the first two weeks to help the skin acclimatize and minimize retinoid dermatitis before advancing to nightly use.

Can Aklief be used for body and back acne? Yes, Aklief is specifically FDA-approved for both facial and truncal acne, including the chest, shoulders, and back. Its rapid metabolic breakdown in the liver prevents significant systemic drug accumulation, making it safe and practical to apply across large body surface areas without excessive blood absorption.

Is Aklief better than tretinoin? Aklief is not universally superior to tretinoin for facial acne, but it offers major advantages for extensive body breakouts and atrophic acne scar reduction. While tretinoin has decades of broader anti-aging data, trifarotene’s RAR-gamma selectivity delivers targeted epidermal clearing with less systemic exposure over large body areas.

How much does Aklief cost without insurance? Without insurance or discounts, a 45g pump of Aklief retails for approximately $920, with GoodRx cash pricing around $690. However, eligible cash-paying patients can pay approximately $90 through the Galderma CAREConnect Patient Savings Card, while commercially insured patients can pay as little as $20.

How long does one 45g pump of Aklief last? A single 45g pump bottle typically lasts between 30 and 45 days when applied to both the face and trunk. If used exclusively on the face (requiring only one metered pump per night), a 45g container can last 60 to 90 days before needing a pharmacy refill.

Bottom line

Trifarotene (Aklief 0.005% cream) represents a significant advancement in dermatological pharmacology as the first selective fourth-generation topical retinoid FDA-approved for both facial and truncal acne. With pivotal Phase III trials demonstrating substantial lesion reductions across the face, chest, and back, alongside clinical evidence supporting atrophic scar improvement, it is an exceptional prescription option for patients struggling with widespread acne. While its retail cash price exceeds $900, manufacturer savings programs from Galderma CAREConnect reduce out-of-pocket costs to $20 to $90. To receive an evaluation from licensed medical providers, teledermatology services like Nurx and Honeydew Care can prescribe Aklief and route it through specialty pharmacies, while services like Curology provide accessible custom compounded retinoid alternatives.

Sources: Tan J, et al. Journal of the American Academy of Dermatology. 2019. PMID 30802558 · Blume-Peytavi U, et al. Journal of the American Academy of Dermatology. 2020. PMID 31306527 · Dreno B, et al. Dermatology and Therapy. 2023. PMID 37838987 · Del Rosso JQ. Journal of Clinical and Aesthetic Dermatology. 2007. PMID 20725554 · Cleveland Clinic: Trifarotene Topical · FDA Drug Approval Package: Aklief (trifarotene) Cream